Abstract:Extracellular vesicles (EVs) are involved in the pathogenesis of neoplastic diseases. Their role in mediating drug resistance has been widely described in several types of cancers, including melanoma. EVs can mediate drug resistance through several different mechanisms, such as drug-sequestration, transfer of pro-survival proteins and RNA, induction of cancer stem cell-like features and interaction with cells of the tumor microenvironment and immune-system. Melanoma is a highly immunogenic tumor originating from the malignant transformation of melanocytes. Several therapeutic strategies currently used in the treatment of melanoma and the combination of BRAF and MEK-inhibitors, as well as immune check-point inhibitors (ICI), have consistently improved the overall survival time of melanoma patients. However, the development of resistance is one of the biggest problems leading to a poor clinical outcome, and EVs can contribute to this. EVs isolated from melanoma cells can contain “sequestered” chemotherapeutic drugs in order to eliminate them, or bioactive molecules (such as miRNA or proteins) that have been proven to play a crucial role in the transmission of resistance to sensitive neoplastic cells. This leads to the hypothesis that EVs could be considered as resistance-mediators in sensitive melanoma cells. These findings are a pivotal starting point for further investigations to better understand EVs’ role in drug resistance mechanisms and how to target them. The purpose of this review is to summarize knowledge about EVs in order to develop a deeper understanding of their underlying mechanisms. This could lead to the development of new therapeutic strategies able to bypass EV-mediated drug-resistance in melanoma, such as by the use of combination therapy, including EV release inhibitors.

Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications

Extracellular Vesicles in Cancer Drug Resistance: Mechanistic Insights and Therapeutic Implications

Extracellular vesicles in anti-tumor drug resistance: Mechanisms and therapeutic prospects

The Role of Tumor‐Derived Extracellular Vesicles in Drug Resistance in Urologic Cancers

Extracellular vesicles in breast cancer drug resistance and their clinical application

Exosome Mediated Multidrug Resistance in Cancer.

Extracellular vesicles in the tumor microenvironment: Therapeutic resistance, clinical biomarkers, and targeting strategies

Extracellular Vesicles in Cancer Drug Resistance: Implications on Melanoma Therapy

Exosomes: A New Pathway for Cancer Drug Resistance

The Role of Extracellular Vesicles in the Hallmarks of Cancer and Drug Resistance

The Roles of Exosomes in Cancer Drug Resistance and Its Therapeutic Application

The Role of Intracellular and Extracellular Vesicles in the Development of Therapy Resistance in Cancer

Extracellular Vesicles for Drug Delivery in Cancer Treatment

Extracellular vesicles in tumor angiogenesis and resistance to anti-angiogenic therapy

The Role and Clinical Applications of Exosomes in Cancer Drug Resistance

Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance

Intercellular transfer of multidrug resistance mediated by extracellular vesicles

Extracellular Vesicles as Drug Targets and Delivery Vehicles for Cancer Therapy

Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications

Engineered extracellular vesicles: A new approach for targeted therapy of tumors and overcoming drug resistance

The application of extracellular vesicles in colorectal cancer metastasis and drug resistance: recent advances and trends